Products

Therapeutic Protein/Peptide Component:

Indication(s): 

Owner

Key Attributes:

Development Status:

• Sustained serum levels within therapeutic range for minimum of 2 weeks
• Prolonged half-life to enable dosing every 2-4 weeks in humans
• Safety profile expected to be comparable to approved product
• Stable liquid small volume injection (27-30 G needle) administered with autoinjector

• Preclinical studies completed in rats and monkeys
• Pharmacokinetics in rats and monkeys
• Proof of concept efficacy in fat-fed streptozotocin-treated rats